Company research
HERON THERAPEUTICS, INC. /DE/
CIK 818033Updated Sep 27, 2026
SecurityHRTX · NASDAQ · equity
Name history
AP PHARMA INC /DE/ · through Jan 7, 2014ADVANCED POLYMER SYSTEMS INC /DE/ · through Apr 6, 2001
HRTX price & chart
Loading TradingView…
NASDAQ:HRTX on TradingView ↗About the company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
In the news
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 ↗
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value News provided by Heron Therapeutics, Inc. Aug 15, 2025, 07:45 ET Share this article Share to X Share this article Share to X CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. ↗
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress News provided by Heron Therapeutics, Inc. Aug 08, 2025, 07:45 ET Share this article Share to X Share this article Share to X Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 mill ↗
Recent filings
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders
Items 1.01, 3.03, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 255,877,000Source | 233,147,000Source | 222,506,000Source | 250,951,000Source |
| Property, Plant and Equipment, NetUSD | 12,403,000Source | 14,863,000Source | 20,166,000Source | 22,160,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 28,647,000Source | 25,802,000Source | 28,677,000Source | 15,364,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 89,587,000Source | 78,881,000Source | 60,137,000Source | 52,049,000Source |
| Inventory, NetUSD | 92,746,000Source | 53,160,000Source | 42,110,000Source | 54,573,000Source |
| Assets, CurrentUSD | 238,066,000Source | 209,014,000Source | 188,774,000Source | 205,435,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,102,000Source | 17,690,000Source | 6,118,000Source | 13,961,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 2,787,000Source | 5,438,000Source | 7,645,000Source |
| Other Assets, NoncurrentUSD | 5,408,000Source | 6,483,000Source | 8,128,000Source | 15,711,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 241,544,000Source | 266,798,000Source | 256,479,000Source | 237,379,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 1,050,000Source | — | — | — |
| Common Stock, Value, IssuedUSD | 1,883,000Source | 1,521,000Source | 1,503,000Source | 1,191,000Source |
| Additional Paid in CapitalUSD | 1,951,185,000Source | 1,884,409,000Source | 1,870,525,000Source | 1,807,855,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,939,789,000Source | -1,919,594,000Source | -1,906,014,000Source | -1,795,455,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,000Source | 13,000Source | 13,000Source | -19,000Source |
| Stockholders' Equity Attributable to ParentUSD | 14,333,000Source | -33,651,000Source | -33,973,000Source | 13,572,000Source |
| Liabilities and EquityUSD | 255,877,000Source | 233,147,000Source | 222,506,000Source | 250,951,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 96,098,000Source | 91,457,000Source | 79,685,000Source | 82,355,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 3,037,000Source | 3,075,000Source | 2,694,000Source |
| Accounts Payable, CurrentUSD | 8,994,000Source | 11,709,000Source | 3,240,000Source | 3,225,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 2,800,000Source | 5,499,000Source |
| Other Liabilities, NoncurrentUSD | 4,808,000Source | 615,000Source | 241,000Source | 241,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 46,600,000Source | 59,300,000Source | 80,400,000Source | 84,900,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -20,195,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,314,000Source | 2,492,000Source | 2,899,000Source | 2,889,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,339,000Source | 12,962,000Source | 32,854,000Source | 42,980,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 10,706,000Source | 18,744,000Source | 8,088,000Source | 16,550,000Source |
| Increase (Decrease) in InventoriesUSD | 31,052,000Source | 11,050,000Source | -12,463,000Source | 6,191,000Source |
| Increase (Decrease) in Accounts PayableUSD | -2,715,000Source | 8,469,000Source | 15,000Source | -578,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -27,591,000Source | -22,529,000Source | -58,789,000Source | -146,912,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 16,009,000Source | 18,714,000Source | 17,995,000Source | -3,324,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 317,000Source | 1,706,000Source | 1,545,000Source | 1,825,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,427,000Source | 940,000Source | 54,107,000Source | 75,059,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,845,000Source | -2,875,000Source | 13,313,000Source | -75,177,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 28,647,000Source | 25,802,000Source | 28,677,000Source | 15,364,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,512,000Source | 4,860,000Source | 3,059,000Source | 2,250,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,339,000Source | 12,962,000Source | 32,854,000Source | 42,980,000Source |
| Amortization of Debt Issuance CostsUSD | 73,000Source | 210,000Source | 206,000Source | 202,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 46,600,000Source | 59,300,000Source | 80,400,000Source | 84,900,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 5,000Source | 1,000Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 27,000Source | -10,000Source | -74,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -11,339,000Source | — | — | — |
| General and Administrative ExpenseUSD | 54,605,000Source | 53,397,000Source | 49,014,000Source | 37,437,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 9,605,000Source | 6,032,000Source | — | — |
| Investment Income, InterestUSD | 1,948,000Source | 3,550,000Source | 3,364,000Source | 1,638,000Source |
| Net Income (Loss) Attributable to ParentUSD | -20,195,000Source | -13,580,000Source | -110,559,000Source | -182,024,000Source |
| Nonoperating Income (Expense)USD | -17,657,000Source | -2,052,000Source | 56,000Source | -7,366,000Source |
| Operating Lease, ExpenseUSD | 3,100,000Source | 3,000,000Source | 2,900,000Source | 2,800,000Source |
| Other Nonoperating Income (Expense)USD | 1,339,000Source | 430,000Source | 560,000Source | -6,530,000Source |
| Proceeds from Issuance of Common StockUSD | 18,307,000Source | — | 29,755,000Source | 75,145,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 154,904,000Source | 144,285,000Source | 127,044,000Source | 107,672,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 41,347,000Source | 38,648,000Source | 65,105,000Source | 54,874,000Source |
| Operating Income (Loss)USD | -2,538,000Source | -11,528,000Source | -110,615,000Source | -174,658,000Source |
| Other Nonoperating Income (Expense)USD | 1,339,000Source | 430,000Source | 560,000Source | -6,530,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -20,195,000Source | -13,580,000Source | -110,559,000Source | -182,024,000Source |
| Earnings Per Share, BasicUSD per share | -0.12Source | -0.09Source | -0.8Source | -1.67Source |
| Earnings Per Share, DilutedUSD per share | -0.12Source | -0.09Source | -0.8Source | -1.67Source |
| Total Revenue | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 166,707,000Source | 152,449,000Source | 138,135,000Source | 108,876Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 166,707,000Source | 152,449,000Source | 138,135,000Source | 108,876Source |
| Interest Expense (non-operating)USD | 9,605,000Source | 6,032,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 116,095,000Source | 117,165,000Source | 172,554,000Source | 282,330,000Source |
| General and Administrative ExpenseUSD | 54,605,000Source | 53,397,000Source | 49,014,000Source | 37,437,000Source |
| Gross ProfitUSD | 113,557,000Source | 105,637,000Source | 61,939,000Source | — |
| Interest ExpenseUSD | — | — | 3,868,000Source | 2,474,000Source |
| Investment Income, InterestUSD | 1,948,000Source | 3,550,000Source | 3,364,000Source | 1,638,000Source |
| Nonoperating Income (Expense)USD | -17,657,000Source | -2,052,000Source | 56,000Source | -7,366,000Source |
| Operating Lease, ExpenseUSD | 3,100,000Source | 3,000,000Source | 2,900,000Source | 2,800,000Source |
| Research and Development ExpenseUSD | 12,429,000Source | 16,683,000Source | 55,897,000Source | 107,506,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 154,904,000Source | 144,285,000Source | 127,044,000Source | 107,672,000Source |
| Selling and Marketing ExpenseUSD | 49,061,000Source | 47,085,000Source | 67,643,000Source | 82,513,000Source |
Filing attachments
hrtx-ex4_1.htm · 8-K · 2026-08-14
EX-4.1 2 hrtx-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO TAX BENEFIT PRESERVATION PLAN This Amendment No. 1 to Tax Benefit Preservation Plan (this “Amendment”) is dated as of August 13, 2026 (the “Effective Date”), and amends that certain Tax Benefit Preservation Plan, dated as of August 14, 2025 (the “Plan”), by and between Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as rights a…
Read attachment ↗hrtx-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF® net revenue grew 35% and APONVIE® net revenue grew 74% year-over-year - Amended credit facility with Hercules Capital: financial covenants reset through 2027, and outstanding principal to be reduced by a total potential reduction of $17.5 million - $13.5 million at execution and a …
Read attachment ↗hrtx-ex99_1.htm · 8-K · 2026-06-02
EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 U.S. District Court Issues Decision Regarding CINVANTI® Patents - After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal - CARY, N.C., June 2, 2026 (GLOBE NEWSWIRE) - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent lit…
Read attachment ↗hrtx-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI® patent litigation - Reaffirmed 2026 full-year guidance of $173 - $183 million net revenue; $10 - $20 million…
Read attachment ↗hrtx-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise - Achieved $154.9 Million in 2025 Net Revenue - Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., February 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or th…
Read attachment ↗hrtx-ex99_1.htm · 8-K · 2026-01-09
EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth CARY, N.C., Jan. 9, 2026 - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum i…
Read attachment ↗